The status quo and analysis of quality control of cancer chemotherapy in 76 hospitals in Beijing
10.3760/cma.j.issn.0253-3766.2018.04.008
- VernacularTitle: 北京市76家医院恶性肿瘤化疗质控现状调查研究
- Author:
Tinglin QIU
1
;
Peiwei YANG
2
;
Guohui LI
3
;
Fei MA
4
;
Ting GAO
1
;
Weilong LIN
1
;
Jianhui MA
1
;
Lühua WANG
5
Author Information
1. Department of Medical Affairs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2. Department of Medical Administration, Beijing Municipal Commission of Health and Family Planning, Beijing 100053, China
3. Department of Pharmacy, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
4. Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
5. Department of Radiation Therapy, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Clinical Trail
- Keywords:
Neoplasms;
Antineoplastic combined chemotherapy protocols;
Quality control
- From:
Chinese Journal of Oncology
2018;40(4):280-283
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Investigated the status quo of quality control of cancer chemotherapy in hospitals in Beijing to discover the main problems and provide the improvement measures.
Methods:One medical record of cancer chemotherapy was taken every month for examination of quality control, and a total of 10 medical records in each hospital were examined. A total of 756 medical records from 76 hospitals were examined.
Results:The results of analysis showed that the overall standardization and quality control of cancer chemotherapy was positively correlated with the grade of hospital. Only 36.8% of the hospitals were equipped with Pharmacy Intravenous Admixture Services (PIVAS). In terms of quality control of chemotherapy and medicine, the department of oncology had better performance than other departments (P<0.01). The scores of quality control of chemotherapy and medicine in the hospitals with clinical specialist pharmacists were 50.6 and 14.5, significantly higher than 47.2 and 12.7 of those without clinical specialist pharmacists (P<0.05).
Conclusion:We should focus on the quality control of cancer chemotherapy in secondary hospitals, reinforce the training of oncology specialists, establish the admission system of oncologists, enhance the training of oncology clinical pharmacists and promote the standardization of cancer chemotherapy.
